- Home
- NKX vs JANX Comparison
NKX vs JANX Comparison
Compare NKX & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NKX | JANX |
|---|---|---|
| Founded | 2002 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 666.9M | 790.3M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | NKX | JANX |
|---|---|---|
| Price | $12.23 | $15.00 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $48.73 |
| AVG Volume (30 Days) | 213.2K | ★ 1.0M |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 4.37% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.45 | $12.12 |
| 52 Week High | $13.20 | $35.34 |
Technical Indicators
Market Signals| Indicator | NKX | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 49.15 | 53.98 |
| Support Level | $11.67 | $13.10 |
| Resistance Level | $12.58 | $15.49 |
| Average True Range (ATR) | 0.08 | 0.61 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 93.09 | 29.53 |
Price Performance
Historical ComparisonAbout NKX Nuveen California AMT-Free Quality Municipal Income Fund
Nuveen California AMT-Free Quality Municipal Income Fund is a closed-end fixed income mutual fund. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Arizona individual income taxes and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued. It invests across sectors such as healthcare, utilities, transportation, and housing.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.